 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Feb 10, 2022 |
| Title |
Correlates of Durability and Boosting Following Ad26.COV2.S Immunization in Rhesus Macaques |
| Organism |
Macaca mulatta |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Ad26.COV2.S is a single-shot vaccine with clinical efficacy against symptomatic COVID-19. In this study, we report the correlates of durability of humoral and cellular immune responses in 20 rhesus macaques immunized with single-shot Ad26.COV2.S and the immunogenicity of a booster shot at 8-10 months following the initial immunization. Innate immune responses, memory B cell responses, and bone marrow plasma cell responses correlated with durable antibody responses following initial vaccination. Following Ad26.COV2.S boost immunization, binding and neutralizing antibody responses increased 31-69 fold and 23-43 fold, respectively, compared with pre-boost levels against multiple SARS-CoV-2 variants, including the delta variant. Antigen-specific B cell and T cell responses also increased. Humoral and cellular immune responses were largely comparable for ancestral, alpha, beta, gamma, delta, and kappa SARS-CoV-2 variants following the boost immunization. Boosting with a modified Ad26.COV2.S.351 vaccine expressing the SARS-CoV-2 beta Spike led to largely comparable responses. These data demonstrate that a late boost with Ad26.COV2.S in rhesus macaques resulted in a dramatic increase in humoral and cellular immune responses that were highly cross-reactive across multiple SARS-CoV-2 variants.
|
| |
|
| Overall design |
20 outbred Indian-origin adult male and female rhesus macaques (Macaca mulatta) ages 4-22 years old were randomly allocated to groups. 5 additional sham rhesus macaques were utilized as controls for the bone marrow biopsies. All animals were housed at Bioqual, Inc. (Rockville, MD). Animals were immunized with 1011 vp (N=10) or 5x1010 vp (N=10) Ad26.COV2.S and were followed for either 230 or 315 days. Animals were then boosted with 5x1010 vp Ad26.COV2.S (N=10) or Ad26.COV2.S.351 (N=10). Half of animals in each original dose group were immunized by each booster vaccine. All immunologic studies were performed blinded. Animal studies were conducted in compliance with all relevant local, state, and federal regulations and were approved by the Bioqual Institutional Animal Care and Use Committee (IACUC).
|
| |
|
| Contributor(s) |
He X, Aid M, Barouch D |
| Citation(s) |
35191769 |
| |
| Submission date |
Jan 07, 2022 |
| Last update date |
May 12, 2022 |
| Contact name |
Dan Barouch |
| Organization name |
BIDMC
|
| Department |
CVVR
|
| Lab |
Barouch Lab
|
| Street address |
3 Blackfan Circle
|
| City |
Boston |
| State/province |
MA |
| ZIP/Postal code |
02215 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL27943 |
Illumina NovaSeq 6000 (Macaca mulatta) |
|
| Samples (10)
|
|
| Relations |
| BioProject |
PRJNA795508 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE193264_geo_submission_processedData_geneExpression.csv.gz |
648.8 Kb |
(ftp)(http) |
CSV |
SRA Run Selector |
| Raw data are available in SRA |
| Processed data are available on Series record |
|
|
|
|
 |
Less...
More...